Upstream diagnostics for biologics process bottlenecks
Metastate helps upstream PD and manufacturing teams identify the dominant constraints behind scale-up divergence, productivity plateaus, and ambiguous troubleshooting signals.
Where Metastate helps
Biologics teams often have enough symptoms to know the process is underperforming, but not enough clarity to choose the next experiments with confidence. The problem may appear as a titer plateau, unstable scale-up, process drift, a raw-material sensitivity, or a handoff between development and manufacturing that exposes hidden constraints.
The diagnostic work starts by making competing explanations explicit. We separate symptoms from mechanisms, map available evidence, and rank which hypotheses are worth testing first. That helps teams avoid a long sequence of disconnected fixes.
Diagnostic output
The output is a ranked decision memo: dominant hypotheses, the evidence supporting or weakening each one, the smallest useful experiment set, and the decision rules for what to do after each result.
This connects directly to bioprocess optimization consulting when the team needs a broader sprint, or to DOE planning when the next round needs better information density.